Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0270 alone or in combination in ER+/HER2- breast cancer
NCT05293964Phase 1Active, not recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- May 2022
- Primary completion
- Dec 2024
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label trial of SIM0270 in breast cancer (3 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose and 1 more. Started May 2022; status: active, not recruiting.
02
Drugs
SIM0270
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05293964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05293964.